Drug Trial Radar · NCT03905525
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
Last checked: Nov 19, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
273
Actual
Start
Oct 1, 2019
Primary completion
Sep 28, 2022
Study completion Jun 6, 2023
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
Conditions
- Sjögren Syndrome
Interventions
CFZ533Drug
Biological
PlaceboOther
liquid placebo for injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Change in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) Score From Baseline at 24 Weeks as Compared to PlaceboTime frame: Baseline, Week 24
- Cohort 2: Change in EULAR Sjögren Syndrome Patient Reported Index (ESSPRI) Score From Baseline at 24 Weeks as Compared to Placebo.Time frame: Baseline, Week 24
Locations
71 sites in 23 countries. Site status is shown where the registry gives one.
North GA Rheumatology Group PC
Suwanee, Georgia
Indiana Univ School of Dentistry
Indianapolis, Indiana
Ochsner Health System
Baton Rouge, Louisiana
The John Hopkins Jerome L Greene Sjogren
Baltimore, Maryland
Tufts School of Dental Medicine
Boston, Massachusetts
Winthrop University Hospital
Mineola, New York
Perelman School of Medicine
Philadelphia, Pennsylvania
Uni Wisconsin School Med Pub Health
Madison, Wisconsin
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
Nedlands, Western Australia, Australia
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Vitória, Espírito Santo, Brazil
Novartis Investigative Site
Juiz de Fora, Minas Gerais, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Rimouski, Quebec, Canada
Novartis Investigative Site
Trois-Rivières, Quebec, Canada
Novartis Investigative Site
Concepción, Chile
Novartis Investigative Site
Valdivia, Los Ríos Region, Chile
Novartis Investigative Site
Santiago, RM, Chile
Novartis Investigative Site
Santiago, Santiago Metropolitan, Chile
Novartis Investigative Site
Santiago, Santiago Metropolitan, Chile
Novartis Investigative Site
Medellín, Antioquia, Colombia
Novartis Investigative Site
Barranquilla, Atlántico, Colombia
Novartis Investigative Site
Cali, Valle del Cauca Department, Colombia
Novartis Investigative Site
Brest, France
Novartis Investigative Site
Le Kremlin-Bicêtre, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Bonn, Germany
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Novartis Investigative Site
Würzburg, Bavaria, Germany
Novartis Investigative Site
Dresden, Saxony, Germany
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Szeged, Hungary
Novartis Investigative Site
Székesfehérvár, Fejér, Hungary
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.